Carl Zeiss introduces its PROVE Registration and Overlay Metrology System for photomasks at SPIE Photomask Conference in Monterey, CA. PROVE measures image placement on photomasks with superior resolution meeting the challenging requirements of the 32nm technology node and beyond.
In addition to its industry-leading lines of compound microscopes and stereomicroscopes, Leica Microsystems offers an innovative series of digital microscopes that bring new levels of flexibility and precision to meet the unique needs of QA professionals inspecting microelectronics and medical devices.
Reinforcing its commitment to researchers and clinicians, GE Healthcare, a unit of General Electric Company is showcasing a comprehensive molecular imaging portfolio - encompassing tracer development, pre-clinical imaging and highly advanced imaging equipment - to provide insight into the origins of disease, at the World Molecular Imaging Congress (WMIC), Booth #212, September 8 through 11 in Kyoto, Japan.
In a further expansion of its sales and service capabilities in the northeast, Olympus America Inc. has announced that it will begin selling and servicing scientific equipment directly in the region surrounding its headquarters in Pennsylvania's Lehigh Valley beginning October 1.
Kopin Corporation, the world's leading producer of heterojunction bipolar transistor wafers for smart phones and other mobile devices, announced today that it has received a two-year, Phase II Small Business Innovative Research (SBIR) contract for the development of Aluminum Indium Nitride-based high electron mobility transistors.
Applied Nanotech Holdings, Inc. is pleased to announce that it has been notified that it has been selected for a SBIR Phase II award to develop carbon foils for the next generation ion beam accelerators. The amount of the award is approximately $750,000.
Tekmira Pharmaceuticals Corporation, a leader in RNA interference (RNAi) therapeutics, today announced that its Investigational New Drug (IND) application for TKM-PLK1 has been cleared by the United States Food and Drug Administration (FDA) allowing Tekmira to initiate a Phase 1 human clinical trial.